Alan Ashworth, PhD, FRS

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Patent
    Ineligible company:
    AstraZeneca
    Topic:
    Use of PARP inhibitors
    Date added:
    09/14/2023
    Date updated:
    09/14/2023

Pages

Return to 2023 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes